Monday, July 25, 2016 10:58:40 PM
Hi Ray,
It affects us all the same way. It simply lowers the stock count, raises the stock price, but the market cap remains the same. I'm all for it if they use it to up list. I can't speak for Dart but imagine he feels the same way. Institutional investors can buy once it gets on an exchange, and that should help the stock see fair value.
A mock example:
So let's say there are 100,000,000 shares and the market cap is 100,000,000 that would be $1 a share.
If it's a 4:1 reverse. The price of the stock would go to $4 a share; the stock count would go to 25,000,000; and the market cap would stay at 100,000,000.
As for the warrants, the same thing. Using the same 4:1 mock example, where the old stock price was $1, but then goes to $4. If he is able to exercise, let's just 10,000,000 warrants, at $.50 and that would represent upon adjusted split he would only get to exercise 2,500,000 warrants; and the exercise price would change to $2. The company would get the same $5,000,000 if he bought them; and he would be able to slowly release to the market at the new stock price of $4, so his profit would change ($5,000,000).
And so really what a split does is give us all an opportunity to have less manipulation of shares, due to less count and a bunch of new buyers. Anytime they feel they have the cash to get away from the day trader swing trading, well I'll be happy about.
My $.02 on splits is they should be done when the market cap is low enough so that folks don't think they can get a better deal on the market cap. There are some who sell their shares as they get convinced it's going to drop and then they miss the opposite move. I truly believe it is based on value and not stock price. Not all reverse splits are bad. Those that R/S lead to more interested buyers, who might not have bought in on an OTC, who are trying to buy reduced float is always a good thing in my book. :)
It affects us all the same way. It simply lowers the stock count, raises the stock price, but the market cap remains the same. I'm all for it if they use it to up list. I can't speak for Dart but imagine he feels the same way. Institutional investors can buy once it gets on an exchange, and that should help the stock see fair value.
A mock example:
So let's say there are 100,000,000 shares and the market cap is 100,000,000 that would be $1 a share.
If it's a 4:1 reverse. The price of the stock would go to $4 a share; the stock count would go to 25,000,000; and the market cap would stay at 100,000,000.
As for the warrants, the same thing. Using the same 4:1 mock example, where the old stock price was $1, but then goes to $4. If he is able to exercise, let's just 10,000,000 warrants, at $.50 and that would represent upon adjusted split he would only get to exercise 2,500,000 warrants; and the exercise price would change to $2. The company would get the same $5,000,000 if he bought them; and he would be able to slowly release to the market at the new stock price of $4, so his profit would change ($5,000,000).
And so really what a split does is give us all an opportunity to have less manipulation of shares, due to less count and a bunch of new buyers. Anytime they feel they have the cash to get away from the day trader swing trading, well I'll be happy about.
My $.02 on splits is they should be done when the market cap is low enough so that folks don't think they can get a better deal on the market cap. There are some who sell their shares as they get convinced it's going to drop and then they miss the opposite move. I truly believe it is based on value and not stock price. Not all reverse splits are bad. Those that R/S lead to more interested buyers, who might not have bought in on an OTC, who are trying to buy reduced float is always a good thing in my book. :)
Recent MRKR News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 09:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 08:30:23 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/20/2026 08:08:49 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/20/2026 08:07:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/20/2026 08:05:49 PM
- Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results • GlobeNewswire Inc. • 03/18/2026 09:31:30 PM
- Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/18/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 09:06:45 PM
- Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology • GlobeNewswire Inc. • 01/26/2026 12:00:00 PM
- Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer • GlobeNewswire Inc. • 01/05/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:10:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:01:15 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 11/17/2025 09:22:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 12:20:47 PM
- Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/14/2025 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:29:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2025 12:36:59 PM
- Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors • GlobeNewswire Inc. • 11/05/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 10:09:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 10:03:27 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 09:54:39 PM
- Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting • GlobeNewswire Inc. • 11/03/2025 02:15:00 PM
- Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program • GlobeNewswire Inc. • 10/06/2025 11:30:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2025 11:30:37 AM
